Eur Rev Med Pharmacol Sci 2020; 24 (17): 9041-9045

DOI: 10.26355/eurrev_202009_22849

Clinical significance of miR-492 in peripheral blood of acute myocardial infarction

L.-L. Guo, H.-H. Chen, F.-C. Qu, Q.-H. Lu

Department of Cardiology, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. haonan@mail.sdu.edu.cn


OBJECTIVE: To detect the potential of microRNA-492 (miR-492) as a diagnostic biomarker of acute myocardial infarction (AMI) in the acute phase.

PATIENTS AND METHODS: A total of 100 AMI patients and 100 controls (non-AMI patients with chest pain) were retrospectively analyzed. Blood samples were collected at 0, 6, 12, and 24 h after admission, followed by detection of the serum miR-492 level. Serum levels of cTnI and creatine kinase-MB (CK-MB) in AMI patients were examined by enzyme-linked immunosorbent assay (ELISA). The potential relationship between miR-492 level with cTnI and CK-MB levels was analyzed by Pearson correlation test. Moreover, diagnostic value of miR-492 was assessed by depicting receiver operating characteristic (ROC) curves.

RESULTS: Serum level of miR-492 achieved the peak at 6 h after admission, which was time-dependently reduced at 12 h and 24 h.  Serum levels of cTnI and CK-MB were higher in AMI patients than those of controls. However, miR-492 level achieved the peak before cTnI and CK-MB increased to the highest levels. MiR-492 level was positively correlated to cTnI and CK-MB levels. ROC curves verified the diagnostic value of miR-492 in AMI (AUC=0.8621, 95% CI=0.8129-0.9112, sensitivity=80%, specificity=75%).

CONCLUSIONS: Serum level of miR-492 remarkably increases in the acute phase of AMI, which may be used as an effective biomarker for diagnosing AMI.

Free PDF Download

To cite this article

L.-L. Guo, H.-H. Chen, F.-C. Qu, Q.-H. Lu
Clinical significance of miR-492 in peripheral blood of acute myocardial infarction

Eur Rev Med Pharmacol Sci
Year: 2020
Vol. 24 - N. 17
Pages: 9041-9045
DOI: 10.26355/eurrev_202009_22849